Gland Pharma Peer Comparison

Gland Pharma Ltd. showcases robust growth metrics and strong profitability compared to its peers in the Pharmaceuticals & Drugs sector, positioning it as a leader. With a low debt-equity ratio and impressive revenue growth, it stands out despite some peers exhibiting higher ROE and EPS figures. Overall, Gland Pharma is well-placed with attractive valuation metrics, making it a compelling investment choice.

• • Gland Pharma has the highest revenue growth YoY at 56.29%.
• • Gland Pharma's debt-equity ratio is among the lowest at 0.0367, indicating low financial risk.
• • Gland Pharma is undervalued based on its PEG ratio of 0.43, suggesting significant growth potential compared to its price.

• • Gland Pharma Ltd.: Highest revenue growth YoY at 56.29% and low debt-equity ratio at 0.0367.
• • Dr. Reddy's Laboratories Ltd.: Strong profitability with ROE at 21.76% and PE ratio at 15.50, making it attractive.
• • Mankind Pharma Ltd.: High growth trajectory with 155.25% revenue growth over 3 years and solid margins.